オクニシ カツヒデ
Okunishi Katsuhide
奥西 勝秀 所属 東邦大学 医学部 医学科 職種 教授 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Targeting activin receptor-like kinase 7 ameliorates adiposity and associated metabolic disorders. |
掲載誌名 | 正式名:JCI insight |
掲載区分 | 国外 |
巻・号・頁 | 8(4) |
著者・共著者 | Min Zhao,Katsuhide Okunishi,Yun Bu,Osamu Kikuchi,Hao Wang,Tadahiro Kitamura,Tetsuro Izumi |
担当区分 | 筆頭著者 |
発行年月 | 2023/02/22 |
概要 | Activin receptor-like kinase 7 (ALK7) is a type I receptor in the TGF-β superfamily preferentially expressed in adipose tissue and associated with lipid metabolism. Inactivation of ALK7 signaling in mice results in increased lipolysis and resistance to both genetic and diet-induced obesity. Human genetic studies have recently revealed an association between ALK7 variants and both reduced waist to hip ratios and resistance to development of diabetes. In the present study, treatment with a neutralizing mAb against ALK7 caused a substantial loss of adipose mass and improved glucose intolerance and insulin resistance in both genetic and diet-induced mouse obesity models. The enhanced lipolysis increased fatty acid supply from adipocytes to promote fatty acid oxidation in muscle and oxygen consumption at the whole-body level. The treatment temporarily increased hepatic triglyceride levels, which resolved with long-term Ab treatment. Blocking of ALK7 signals also decreased production of its ligand, growth differentiation factor 3, by downregulating S100A8/A9 release from adipocytes and, subsequently, IL-1β release from adipose tissue macrophages. These findings support the feasibility of potential therapeutics targeting ALK7 as a treatment for obesity and diabetes. |
DOI | 10.1172/jci.insight.161229 |
PMID | 36626233 |